News | September 17, 2007

DuraHeart Hits a 77 Percent Survival Rate

September 18, 2007 - The DuraHeart Left Ventricular Assist System (LVAS) reported a survival rate of 77 percent for all patients at 1 and 2 years, according to Aly El-Banayosy, M.D., from the Heart Center Nordrhein-Westfalen in Bad Oeynhausen, Germany, who presented a summary of the results from the European Clinical Trial at the European Association of Cardio-Thoracic Surgeons (EACTS) meeting in Geneva, Switzerland.

The clinical results from the 33 patient study on the DuraHeart device, manufactured by Terumo Heart Inc., which had a median age of 57 years of age (29-73), included:
* mean support duration (days) = 231±194 (range: 17-803)
* cumulative support duration = 7610 days (> 20 years)
* 7 patients (21%) supported > 1 year, and one supported > 2 years.
* 12 patients (36%) remain on support with a mean duration > 1 year (375± 196 days)
* Kaplan Meier survival at 1 and 2 years was: 77% (all patients), 80% (

The DuraHeart LVAS is a third generation circulatory support device intended to provide cardiac support for patients who are at risk of death due to end-stage left ventricular failure. It is currently the only approved implantable LVAS combining a centrifugal pump with magnetic levitation of the impeller, reportedly minimizing the potential for blood damage and thrombus. DuraHeart is not available in the United States.

For more information: www.terumo.com

Related Content

Sponsored Content | Videos | Cardiovascular Ultrasound| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Italian Boy Becomes Youngest Patient Bridged to Transplant With SynCardia Total Artificial Heart

Andrei, 12, is the world’s youngest patient to be bridged to transplant with the SynCardia Total Artificial Heart. He is pictured after his heart transplant with his surgeon, Antonio Amodeo, M.D., at Bambino Gesù Children’s Hospital in Rome, Italy. Photo courtesy of Business Wire.

News | Congenital Heart| June 22, 2017
A 12-year-old boy at Bambino Gesù Children’s Hospital in Rome, Italy, has become the world’s youngest patient to be...
Abiomed Impella CP pVAD, third-generation CP
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — Abiomed Inc.
tandemLife Tandemheart priming tray cleared by FDA
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — TandemLife began its commercial launch of the TandemLife Priming Tray, a new product designed to simp
Sponsored Content | Videos | Cardiovascular Ultrasound| May 26, 2017
This video, provided in partnership with the American Society of Echocardiography (ASE), is titled "Intraoperative Tr
Impella CP study to investigate door to left ventricular unloading time
News | May 09, 2017
May 9, 2017 — The first patient has been enrolled in the U.S.
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
the Impella pVAD improves survival, mortality in AMI heart attack with cardiogenic shock

Early use of the Impella percutaneous ventricular assist device prior to angioplasty may significantly improve survival for patients in cardiogenic shock.

Feature | Hemodynamic Support Devices| April 28, 2017 | Dave Fornell
Recent clinical study data presented at the American College of Cardiology (ACC) 2017 meeting show new treatment prot
Sponsored Content | Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Overlay Init